NASH clinical trial presentation and continued revenue growth
November 09 2018 - 6:00AM
Key Highlights:
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the treatment of many gut mediated
diseases, today announced that the IMM-124E NASH clinical study
findings will be presented by Professor Arun Sanyal at the American
Association for the study of Liver Disease which will be held in
San Francisco, California during the 9th – 13th of November 2018.
The presentation entitled “IMM-124E Improves
Metabolic Endotoxemia and Markers of Liver Injury in Non-Alcoholic
Steatohepatitis” will be on the 11th of November 2018 at the Novel
Therapeutics for NASH session. A copy of the presentation will be
made available on Immuron’s website at www.immuron.com.
Travelan was on display at HealthEd, the
Australian General Practitioner conference series, in Sydney,
Melbourne and Brisbane. At these events, Dr. Bernie Hudson, a
respected key opinion leader in Travel Medicine, presented the
latest research on travellers’ diarrhoea to an audience of over
2,000 medical professionals. Key research data on Travelan® and its
efficacy was included in this educational piece.
The company is pleased to report the sales
results of its commercially available and over-the-counter
gastrointestinal and digestive health supplement Travelan®, for the
fiscal year first quarter ending on September 30, 2018.
Australian Travelan® sales reached $340K AUD in
the first quarter of CY19, compared to $330K in the same period of
last financial year. In the month of September 2018, Australian
Travelan sales climbed to $142K AUD, showing a strong 20% increase
from the same month of last financial year.
Global Immuron Limited revenue for Q1 CY2018,
reached $482K AUD before rebates, compared to $475K last financial
year.
Immuron CEO Jerry Kanellos states, “We are
pleased that Professor Arun Sanyal will be sharing our clinical
study findings at this important meeting. The company’s focus since
reporting the topline results of the study in March this year has
been on completing the final clinical study report and we are
currently working with our contract research organization partners
to complete the final analysis of the data generated, and
additional tests currently being performed. The final clinical
study report should be completed by the end of this year and the
plan is to submit it in the new year according to the FDA Code of
Federal Regulations (42 CFR Part 11) – Clinical Trials Registration
and Result Information Submission guidelines.”
ABOUT IMMURON:Immuron Limited (ASX: IMC,
NASDAQ: IMRN), is an Australian microbiome biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases. Immuron has a unique and safe
technology platform that enables a shorter development therapeutic
cycle. The Company currently markets and sells Travelan® for the
prevention of Travelers’ Diarrhea and its lead clinical candidate,
IMM-124E, is in Phase II clinical trials for Non-Alcoholic
Steatohepatitis (NASH), Severe Alcoholic
Hepatitis (SAH) and Pediatric Nonalcoholic Fatty
Liver Disease (NAFLD). Immuron’s second clinical stage
asset, IMM-529, is targeting Clostridium difficile
Infections (CDI). These products together with the
Company’s other preclinical immunotherapy pipeline products
targeting immune-related diseases currently under development, will
meet a large unmet need in the global immunotherapy market.
For more information visit: http://www.immuron.com.
FORWARD-LOOKING STATEMENTS:This
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; risks
relating to the results of research and development activities;
risks relating to the timing of starting and completing clinical
trials; uncertainties relating to preclinical and clinical testing;
our dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
COMPANY CONTACT:
Jerry Kanellos
Chief Executive Officer
Ph: +61 (0)3 9824 5254
jerrykanellos@immuron.com
AUS INVESTOR RELATIONS:
Peter Taylor
NWR Communications
Ph: +61 (0)4 1203 6231
peter@nwrcommunications.com.au
USA INVESTOR RELATIONS:
Dave Gentry - CEO
RedChip Companies, Inc.
US Ph: +1 (407) 491 4498
dave@redchip.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024